Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipients, meeting the primary endpoint. At least 90% improvement in psoriasis severity occurred in 86% of the high-dose group. The study enrolled 187 patients across four treatment groups. Treatment-emergent adverse events affected 39% of high-dose recipients versus
0